Investing.com -- Moderna (NASDAQ: MRNA) shares dropped 13% pre-open on Monday as investors reacted to the weekend news that the U.S. Food and Drug Administration’s (FDA) top vaccine official, Dr.
The resignation of one of the FDA's top officials, Peter Marks, is worrying Wall Street as they await a replacement.
2-Year U.S. Treasury Note Continuous Contract $103.695 0.105 0.10% 5-Year U.S. Treasury Note Continuous Contract $108.453 0.266 0.25% 10-Year U.S. Treasury Note Continuous Contract $111.594 0.391 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback